RET and cancer: The molecular landscapes for several subtypes of human TC have been previously reported12–16, while few targeted genetic studies have been reported in dogs.17–19 In humans, the most common cancer drivers in PTC are BRAF (48%), NRAS (7%), and HRAS (3%), whereas activating mutations in RET or RAS drive MTC12,20.